Anavex Life Sciences Strengthens its Scientific Advisory Board with Distinguished Researcher for Clinical Treatment of Parkinson’s Disease Dementia (PDD)
First Patient Enrolled in Anavex Life Sciences Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease Dementia (PDD)
Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett Syndrome
First Patient Enrolled in Anavex Life Sciences Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease
